Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi

Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi

Submitted by admin on March 11, 2024 - 11:32am
Source: 
Fierce Pharma
News Tags: 
Viatris
FDA
Mapi Pharma
MS
multiple sclerosis
glatiramer acetate depot
Headline: 
Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi
snippet: 

Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Copaxone.

Do Not Allow Advertisers to Use My Personal information